Cancer
Conditions
Brief summary
Multicentric prospective study with collection of biological samples as part of type II research
Interventions
OTHERStool
collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
OTHERBlood sample
20 mL collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
Sponsors
Gustave Roussy, Cancer Campus, Grand Paris
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patient with cancer who will start treatment anticancer (see cohorts). * Patient information and signature of the consent form before any specific procedure for the study. The patient must be able and must be inclined to cooperate in the study procedures. * Patient affiliated to a social security scheme or beneficiary of a similar scheme.
Exclusion criteria
* Pregnant or lactating woman * Patient under guardianship or curatorship or deprived of liberty by a decision judicial or administrative or patient unable to give his consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | Up to 2 years | To define metagenomic signatures associated with cancer |
Countries
France
Contacts
Primary ContactLaurence Zitvogel, MD, PhD
Backup ContactLisa Derosa, MD, PhD
Outcome results
None listed